Gastric Mobility and Gastrointestinal Hormones in Older Patients with Sarcopenia
- PMID: 35565864
- PMCID: PMC9103579
- DOI: 10.3390/nu14091897
Gastric Mobility and Gastrointestinal Hormones in Older Patients with Sarcopenia
Abstract
Sarcopenia has serious clinical consequences and poses a major threat to older people. Gastrointestinal environmental factors are believed to be the main cause. The aim of this study was to describe the relationship between sarcopenia and gastric mobility and to investigate the relationship between sarcopenia and the concentration of gastrointestinal hormones in older patients. Patients aged ≥ 75 years were recruited for this prospective study from August 2018 to February 2019 at the emergency department. The enrolled patients were tested for sarcopenia. Gastric emptying scintigraphy was conducted, and laboratory tests for cholecystokinin(CCK), glucagon-like peptide-1 (GLP-1), peptide YY (PYY), nesfatin, and ghrelin were performed during the fasting period. We enrolled 52 patients with mean age of 86.9 years, including 17 (32.7%) patients in the non-sarcopenia group, 17 (32.7%) patients in the pre-sarcopenia group, and 18 (34.6%) in the sarcopenia group. The mean gastric emptying half-time had no significant difference among three groups. The sarcopenia group had significantly higher fasting plasma concentrations of CCK, GLP-1, and PYY. We concluded that the older people with sarcopenia had significantly higher plasma concentrations of CCK, GLP-1, and PYY. In the elderly population, anorexigenic gastrointestinal hormones might have more important relationships with sarcopenia than orexigenic gastrointestinal hormones.
Keywords: gastric emptying; gastrointestinal hormones; older patients; sarcopenia.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Effects of age on concentrations of plasma cholecystokinin, glucagon-like peptide 1, and peptide YY and their relation to appetite and pyloric motility.Am J Clin Nutr. 1999 May;69(5):999-1006. doi: 10.1093/ajcn/69.5.999. Am J Clin Nutr. 1999. PMID: 10232642 Clinical Trial.
-
Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations.J Clin Endocrinol Metab. 2008 Oct;93(10):3995-8. doi: 10.1210/jc.2008-0924. Epub 2008 Jul 22. J Clin Endocrinol Metab. 2008. PMID: 18647814 Clinical Trial.
-
Effects of L-Phenylalanine on Energy Intake and Glycaemia-Impacts on Appetite Perceptions, Gastrointestinal Hormones and Gastric Emptying in Healthy Males.Nutrients. 2020 Jun 16;12(6):1788. doi: 10.3390/nu12061788. Nutrients. 2020. PMID: 32560181 Free PMC article. Clinical Trial.
-
Gastrointestinal hormones and regulation of food intake.Horm Metab Res. 2004 Nov-Dec;36(11-12):846-51. doi: 10.1055/s-2004-826174. Horm Metab Res. 2004. PMID: 15655718 Review.
-
Effect of Sleeve Gastrectomy on Ghrelin, GLP-1, PYY, and GIP Gut Hormones: A Systematic Review and Meta-analysis.Ann Surg. 2020 Jul;272(1):72-80. doi: 10.1097/SLA.0000000000003614. Ann Surg. 2020. PMID: 31592891
Cited by
-
Sarcopenia-related changes in serum GLP-1 level affect myogenic differentiation.J Cachexia Sarcopenia Muscle. 2024 Oct;15(5):1708-1721. doi: 10.1002/jcsm.13524. Epub 2024 Jun 26. J Cachexia Sarcopenia Muscle. 2024. PMID: 38926763 Free PMC article.
-
Could Naringenin Participate as a Regulator of Obesity and Satiety?Molecules. 2023 Feb 2;28(3):1450. doi: 10.3390/molecules28031450. Molecules. 2023. PMID: 36771113 Free PMC article. Review.
-
Type 2 diabetes mellitus related sarcopenia: a type of muscle loss distinct from sarcopenia and disuse muscle atrophy.Front Endocrinol (Lausanne). 2024 May 24;15:1375610. doi: 10.3389/fendo.2024.1375610. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38854688 Free PMC article. Review.
References
-
- Chen L.K., Woo J., Assantachai P., Auyeung T.W., Chou M.Y., Iijima K., Jang H.C., Kang L., Kim M., Kim S., et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J. Am. Med. Dir. Assoc. 2020;21:300–307.e2. doi: 10.1016/j.jamda.2019.12.012. - DOI - PubMed
MeSH terms
Substances
Grants and funding
- MOST107-2314-B-075-053 and MOST108-2314-B-075-034/Ministry of Science and Technology, Taiwan
- 107VACS-002, 108VACS-002, 109VACS-002, 110VACS-009/Veterans Affairs Council, Taiwan
- VGHUST 110-G7-6-2/Veterans General Hospitals and University System of Taiwan Joint Research Program
- V108C-123, V111C-195/intramural grants from Taipei Veterans General Hospital
LinkOut - more resources
Full Text Sources